<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265915</url>
  </required_header>
  <id_info>
    <org_study_id>J0546 CDR0000450145</org_study_id>
    <secondary_id>P01CA081534</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0546</secondary_id>
    <secondary_id>JHOC-05070103</secondary_id>
    <secondary_id>CLLRC-008</secondary_id>
    <nct_id>NCT00265915</nct_id>
  </id_info>
  <brief_title>Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A CRC Trial of Rituximab in Combination With Sargramostim (GM-CSF) in Patients With Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different&#xD;
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and&#xD;
      help kill them or carry cancer-killing substances to them. Colony-stimulating factors, such&#xD;
      as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood.&#xD;
      Giving rituximab together with GM-CSF may be an effective treatment for chronic lymphocytic&#xD;
      leukemia.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving rituximab together with GM-CSF works&#xD;
      in treating patients with B-cell chronic lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the complete and overall response rate in patients with B-cell chronic&#xD;
           lymphocytic leukemia treated with rituximab and sargramostim (GM-CSF).&#xD;
&#xD;
        -  Determine the time to progression in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the effects of this regimen on CD20 antigen expression and soluble CD20 levels&#xD;
           in these patients.&#xD;
&#xD;
      OUTLINE: This is a parallel-group, multicenter study. Patients are stratified according to&#xD;
      disease status&#xD;
&#xD;
      Patients receive rituximab IV on days 4, 11, 18, and 25 and sargramostim (GM-CSF)&#xD;
      subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, 40,&#xD;
      43, 45, 47, 50, 52, and 54 (course 1). Patients with responding disease may receive an&#xD;
      additional course of treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for up to 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 130 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
  </primary_outcome>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of B-cell chronic lymphocytic leukemia meeting 1 of the following criteria:&#xD;
&#xD;
               -  Previously treated stage III or IV or earlier stage disease with evidence of&#xD;
                  active disease, as defined by ≥ 1 of the following:&#xD;
&#xD;
                    -  Weight loss &gt; 10% within the past 6 months&#xD;
&#xD;
                    -  Extreme fatigue&#xD;
&#xD;
                    -  Fever or night sweats without evidence of infection&#xD;
&#xD;
                    -  Worsening anemia or thrombocytopenia&#xD;
&#xD;
                    -  Progressive lymphocytosis with a rapid lymphocyte doubling time&#xD;
&#xD;
                    -  Marked hypogammaglobulinemia or paraproteinemia&#xD;
&#xD;
                    -  Lymphadenopathy &gt; 5 cm in diameter&#xD;
&#xD;
               -  Previously untreated stage 0-II disease with symptoms or significant fatigue or&#xD;
                  at high risk of progression due to of B2 microglobulin &gt; 3.0 mg/mL&#xD;
&#xD;
               -  Patients who are ≥ 70 years of age with previously untreated stage III or IV or&#xD;
                  earlier stage disease requiring treatment but who refused chemotherapy are&#xD;
                  eligible&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL* (elevated bilirubin allowed if due to of Gilbert's disease)&#xD;
             NOTE: *Liver dysfunction due to lymphocytic organ infiltration allowed&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2.5 mg/dL* NOTE: *Renal dysfunction due to lymphocytic organ infiltration&#xD;
             allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active viral infection (e.g., viral hepatitis)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian W. Flinn, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>December 14, 2005</study_first_submitted>
  <study_first_submitted_qc>December 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <last_update_submitted>August 11, 2014</last_update_submitted>
  <last_update_submitted_qc>August 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2014</last_update_posted>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage 0 chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

